Search Site


3M Unveils Intelligent Inhaler Designed to Help Control Spiraling Costs of Respiratory Disease

Tuesday, April 19, 2016

Technology aims to solve patient competence and adherence challenges, minimizing burden on health care providers and payers

ST. PAUL, Minn.--(BUSINESS WIRE)-- Research shows that an estimated 334 million people have asthma worldwide, and 65 million people have moderate to severe COPD - a number that is expected to rise 24 percent by the year 2034 to make COPD the world’s third leading cause of death.(1,2,3) As cases increase, driven by the aging population, hospitals and care providers continue to see low levels of adherence and poor and inconsistent competence using current treatment devices. This has led to sub-optimal outcomes and higher rates of hospital admissions. Answering the need for a solution to device misuse and adherence issues, 3M Drug Delivery Systems introduces the 3M™ Intelligent Control Inhaler, an intuitive, fully-integrated device that delivers accurate doses to patients, whilst providing on-screen instructions for use and feedback to the patient and health care provider via an app.

This Smart News Release features multimedia. View the full release here:

3M Drug Delivery Systems Unveils 3M(tm) Intelligent Control Inhaler (Photo: 3M)

3M Drug Delivery Systems Unveils 3M(tm) Intelligent Control Inhaler (Photo: 3M)

“Providing an effective and intuitive delivery method for respiratory disease treatment is critical to patients, health care providers and payers alike,” said Louise Righton, Global Marketing Operations Manager, 3M Drug Delivery Systems. “Poor technique in using an inhaler, coupled with the challenges of getting patients to adhere to their medication protocols, can lead to exacerbations, increased use of health care resources and ultimately, a burden on health care systems. By increasing competence and adherence, we can realize better patient outcomes and reduce health care costs.”

The 3M Intelligent Control Inhaler provides a number of unique features that offer opportunities to improve outcomes by reducing patient variability and errors, and providing data on use to health care providers and payers:

  • Controlled inspiration: a combination of breath actuation with innovative technology to control inspiratory flow rate significantly reduces errors in technique, and results in a much higher level of consistency of drug delivery between breaths and between patients.
  • Integrated patient instructions: the inhaler’s patient-proof design gives patients confidence to use the inhaler correctly and helps eliminate critical errors in use, as well as minimizing the resources dedicated to training patients in correct inhalation technique.
  • Fully integrated device: the dose is registered when the patient correctly inhales medication rather than on actuation of the device, delivering greater accuracy of information for the patient, and cost-savings for health care providers who can avoid unnecessary switches and treatment escalation.
  • Capture of inspiration data: the inhaler utilizes a data management platform to record not only device usage, but also inspiration profiles to help monitor disease progression, further supporting informed treatment decisions.

The device will be developed in partnership with a pharmaceutical company, and is expected to be in wide use by the end of the decade.

“We’ve done a tremendous amount of research during the development of this technology with patients, health care providers, and payers,” said Dr Steven Wick, Technical Director, 3M Drug Delivery Systems. “With 60 years of experience in inhalation technologies, and 30 years in health information systems, 3M is uniquely qualified to bring forth a solution that is a definitive win for each of these stakeholders. Nothing has worked to improve inhaler technique over the past 25 years – and here we have a connected device to improve both competence AND adherence. The need for a smarter solution has never been greater, and 3M intends to put greater control of respiratory disease into the hands of patients, health care providers and payers.”

For more information on the 3M Intelligent Control Inhaler, call 1-800-643-8086 (US), 44-1509-613034 (UK) or click here.

About 3M Drug Delivery Systems

3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop and manufacture pharmaceutical products using 3M's inhalation, transdermal or microneedle drug delivery technology. 3M offers a full range of feasibility, development and manufacturing capabilities to help bring products to market. Regulatory expertise, quality assurance, operations, marketed product support and other in-house resources are available for each step of the development and commercialization process. For more information, please visit or call 1-800-643-8086.

About 3M

At 3M, we apply science in collaborative ways to improve lives daily. With $30 billion in sales, our 90,000 employees connect with customers all around the world. Learn more about 3M’s creative solutions to the world’s problems at or on Twitter @3M or @3MNewsroom.

3M is a trademark of 3M Company.

1 World Health Organisation. Available at: [last accessed November 26, 2015]

2 COPD: Chronic Obstructive Pulmonary Disease

3 Datamonitor Healthcare. Chronic obstructive pulmonary disease: Epidemiology. 2015

Source: 3M

For 3M

Michael Gugala, 612-342-9604

Karwoski & Courage

Please note that you are now entering a website directly or indirectly maintained by a third party (the "External Site") and that you do so at your own risk.

3M has no control over the External Site, any data or other content contained therein or any additional linked websites. The link to the External Site is provided for convenience purposes only.

By entering this site you acknowledge and agree that neither 3M nor the third party provider, Virtua Research, Inc. (“Virtua”), is responsible, or accepts or assumes any responsibility or liability whatsoever for, the content, the data or the technical operation of the External Site. Further, by entering the External Site, you also acknowledge and agree that you completely and irrevocably waive any and all rights and claims against 3M and Virtua and further acknowledge and agree that in no event shall 3M or Virtua, its officers, employees, directors and agents be liable for any (i) indirect, consequential, incidental, special, compensatory or punitive damages, (ii) damages for loss of income, loss of business profits, business interruption, loss of data or business information, loss of or damage to property, (iii) claims of third parties, or (iv) other pecuniary loss, arising out of or related to Legal, this disclaimer or the External Site.

By entering the External Site, you further acknowledge and agree that the disclaimer of warranties and limitations of liability set out in this disclaimer shall apply regardless of the causes, circumstances or form of action giving rise to the loss, damage, claim or liability, even if such loss, damage, claim or liability is based upon breach of contract (including, without limitation, a claim of fundamental breach or breach of a fundamental term), tort (including, without limitation, negligence), strict liability or any other legal or equitable theory, and even if 3M and Virtua are advised of the possibility of the loss, damage, claim or liability. The waiver and release specifically includes, without limitation, any and all rights and claims pertaining to the processing of personal data, including but not limited to any rights under any applicable data protection statute(s).

If in any jurisdiction, any part of this disclaimer is held to be unenforceable by a court of competent jurisdiction, such part of this disclaimer shall be restricted or eliminated to the minimum extent and the remaining disclaimer shall otherwise remain in full force and effect.

The reports of 3M contained on the External Site contain forward-looking information about 3M’s financial results and estimates and business prospect that involve substantial risks and uncertainties. You can identify these statements by the use of words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “will,” “target,” “forecast” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are factors described in 3M’s most recent Annual Report on Form 10-K under “Cautionary Note Concerning Factors That May Affect Future Results” in Part I, Item 1. Additional factors that could cause 3M’s results to differ materially from those described in the forward-looking statements can be found under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in 3M’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are filed with the SEC. 3M assumes no obligation to update any forward-looking statements contained in the reports contained on the External Site as a result of new information or future events or developments.

The reports contained on the External Site were, to the best of 3M’s knowledge, timely and accurate on the date they were issued. The passage of time can render information stale. You should not rely on the continued accuracy of any information beyond the date it was issued. 3M has no responsibility to update any information contained in any report on the External Site. You should note the date any report on the External Site was issued.